A study presented at the AACR Annual Meeting 2013 indicates that a DNA blood test using Inostics' BEAMing Digital PCR can detect more mutations associated with secondary drug resistance in GIST patients than testing conventional biopsies. Therapies targeted to specific cancer-causing mutations may be the most promising strategy in cancer treatment. However, inter- and intra-tumor heterogeneity pose a significant challenge to maximizing therapeutic efficacy...
More...
More...